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Abstract 
 
Impaired skin wound healing is a major medical problem in diabetic subjects. Kinins exert 
a number of vascular and other actions limiting organ damage in ischemia or diabetes but 
their role in skin injury is unknown. We investigated, through pharmacological manipulation 
of kinin B1 and B2 receptors (B1R/B2R), the role of kinins in wound healing in non-diabetic 
and diabetic mice.  
Using two mouse models of diabetes (streptozotocin-induced and db/db mice) and non-
diabetic mice, we assessed effect of kinin receptor activation or inhibition by subtype 
selective pharmacological agonists (B1R and B2R) and antagonist (B2R) on healing of 
experimental skin wound. We also studied effects of agonists and antagonist on keratinocytes 
and fibroblasts in vitro. 
B1 and B2 receptor mRNAs level increased one to two fold in healthy and wounded 
diabetic skin compared to non-diabetic skin. Diabetes delayed wound healing. B1R agonist 
had no effect on wound healing. In contrast, B2R agonist impaired wound repair in both non-
diabetic and diabetic mice, inducing skin disorganization and epidermis thickening. In vitro, 
B2R activation unbalanced fibroblast/keratinocyte proliferation and increased keratinocyte 
migration. These effects were abolished by co-administration of B2R antagonist. 
Interestingly, in the two mouse models of diabetes B2R antagonist administered alone 
normalized wound healing. This effect was associated with induction of MCP1/TNFα 
mRNAs. 
Thus, stimulation of kinin B2 receptor impairs skin wound healing in mice. B2R activation 
occurs in the diabetic skin delays wound healing. B2R blockade improves skin wound healing 
in diabetic mice and is a potential therapeutic approach to diabetic ulcers. 
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Abbreviations 
 
ACE: Angiotensin I-converting enzyme 
AT1R: Angiotensin II type 1 receptor 
AT2R: angiotensin II type 2 receptor 
AU: arbitrary units 
B1R: bradykinin type-1 receptor  
B2R: bradykinin type-2 receptor  
B1R-ag: bradykinin type-1 receptor agonist 
B2R-ag: bradykinin type-2 receptor agonist 
B2R-ant: bradykinin type-2 receptor antagonist 
Diab: diabetic 
DMEM: Dulbecco’s Modified Eagle Medium 
ERK1/2: p44/42 MAP-Kinase 
FBS: Foetal Bovine Serum 
IL-6: Interleukine 6 
KKS: Kallikrein-Kinin(s) System 
MCP-1: Monocyte Chemoattractant Protein-1 
NBCS: New Born Calf Serum 
NonDiab: non-diabetic 
PBS: Phosphate Buffered Saline 
SAP: Serum amyloid P 
STZ: streptozotocin 
STZ-Diab: diabetes induced by streptozotocin  
TGF-beta: Transforming growth factor beta 
TNF-alpha: Tumor Necrosis Factor alpha 
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Introduction 
Impaired skin wound healing is a source of morbidity, disability, loss of quality of life 
and mortality in subjects affected by diabetes. Foot ulcers affect at least once in their life 
about 15% of patients with diabetes. Amputation rate is high in affected patients[1-3]. The 
pathogenesis of chronic foot ulcers is multifactorial and still incompletely understood. Loss of 
insulin action, hyperglycaemia, ischemia secondary to micro- and macro-angiopathy, 
neuropathy and infection all contribute to delayed skin repair and favour tissue necrosis, 
increasing amputation risk[4]. Improving skin wound healing in patients with diabetes is an 
important therapeutic issue. 
Skin healing after wounding involves several different biological processes and 
comprises an acute response phase with haemostasis and inflammation, a granulation phase 
with cell migration, angiogenesis, production of extracellular matrix, wound contraction and 
re-epithelisation and a late scar maturation phase. Various cell types are involved in these 
processes: platelets, inflammatory cells, endothelial cells, fibroblasts and keratinocytes[5]. In 
diabetes, all phases of wound healing are altered. Cellular infiltration, migration and 
proliferation, and granulation tissue formation are delayed, together with impaired collagen 
organization and reduced angiogenesis[5]. Moreover, chronic hyperglycaemia alters 
fibroblasts and keratinocytes phenotypes. While impairment of the different components of 
the healing process has been documented in diabetes, therapeutic options for improving 
wound healing in diabetic subjects remain currently limited. 
The kallikrein-kinin system (KKS) is implicated in physiological vasodilatation[6,7], 
anticoagulation[8], inflammation[9], and angiogenesis[10]. Previous studies have documented 
the role of this system in limiting organ damage in the setting of hemodynamic, 
hyperglycaemic or ischemic aggression[7,11]. We hypothesized that KKS could play a role in 
cutaneous responses to injury, especially in diabetes. Indeed, kinins have several cellular 
targets involved in skin repair including platelets, endothelial cells, keratinocytes and 
fibroblasts. Studies have documented the presence of the different components of the KKS in 
healthy, traumatized or diseased human skin[12-16]. Kinin receptors, bradykinin type-1 
receptor (B1R) and bradykinin type-2 receptor (B2R), have been shown to participate in 
hyperproliferative process in chronic skin inflammation model[17]. Kinins increase skin 
microvascular blood flow in rabbits and humans[18]. These studies suggest a role for KKS in 
skin physiology. However, involvement of KKS in skin repair in the setting of diabetes 
remains undocumented. 
The aim of the present study was to investigate the role of kinins and their receptors in 
wound healing in diabetic mice, and to compare with non-diabetic animals. Effect of potent 
selective pharmacological B1R or B2R agonists and/or of B2R antagonist was studied in vivo 
in mice and in vitro in cultured fibroblasts and keratinocytes. The study shows that a) B2R 
stimulation has deleterious effects in the wounded skin, unbalancing fibroblast/keratinocyte 
proliferation and migration and delaying cicatrisation; b) B2R activation occurs in the diabetic 
skin and impairs wound healing; c) B2R blockade improves wound healing in diabetic mice. 
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Materials and methods 
Animals, experimental protocols and treatments  
 
Effects of B1R or B2R agonists or B2R antagonist on wound healing were studied, in both 
non-diabetic (NonDiab) and diabetic (Diab) mice. All mice were housed with a 12 h 
light/dark cycle and had free access to standard mice chow and water. All experimental 
procedures were approved by the local Ethics Committee for Animal Experiment Charles 
Darwin and performed in accordance with European legislation for the care and use of 
laboratory animals (L 358-86/609/EEC). 
 
Murine model of type 1 diabetes Diabetes was induced in 10 weeks-old mice (C57BL/6J 
strain, male, Charles River Laboratories, France) by 5 daily i.p. injections of streptozotocin 
(STZ) (Sigma-Aldrich, France) (50 mg/kg body weight in 0.05 mol/L-1 sodium citrate, pH 
4.5)[10,19]. Diabetes was confirmed by assessing fasting blood glucose level at 0, 7 and 30 
days post STZ injection. After 5 weeks of confirmed diabetes (fasting blood glucose>300 
mg/dl), excisional wounds were created on the back of the mice as described below. Control 
NonDiab animals were treated with vehicle only.  
 
Murine model of type 2 diabetes Diabetic db/db mice were obtained from Janvier Labs 
(Saint-Berthevin, France). Experiments were performed on male mice, 12 week-old. Only 
mice with 4 weeks of fasting blood glucose>300 mg/dl were used.  
 
Murine model of skin wound healing Animals were anesthetized by isoflurane inhalation 
(1.5% in O2). A dorsal 8 mm diameter full-thickness wound was made on dorsal depilated 
and cleaned (povidone-iodine solution) skin using a sterile biopsy punch (Kai medical, 
Japan)[20,21]. Buprenorphine (0.05 mg/kg; Buprécare, Axience, France) was administered as 
analgesic agent ten minutes prior and 24 hours after biopsy. Wounds were harvested by taking 
high-resolution photos every 2-3 days and the area was quantified relative to a millimetre 
reference using Image Analyzer Software (ImageJ, NIH) and expressed as percentage of 
wound area measured at day 0. At day 11 after injury, corresponding to wound closure of 
NonDiab mice, animals were sacrificed by pentobarbital overdose (120 mg/kg) and a skin 
sample including wound and surrounding tissues was collected. One half of the sample was 
immediately fixed in 10% formalin for histological analysis, the other part being kept at -
80°C for molecular analyses.  
 
Treatments administration Immediately after wounding, mice were implanted i.p. with 
osmotic minipumps (Alzet, model 1002, Charles River, France) delivering the selective B1R 
agonist (SarLys[Hyp3,Igl5,DPhe8]desArg9-bradykinin, B1R-ag) or the selective B2R agonist 
([Hyp(3),Thi(5),(N)Chg(7),Thi(8)]-bradykinin, B2R-ag)[22,23], both at non-hypotensive dose 
of 720 nmol/kg.day-1 (B1R-ag: 796 µg/kg.day-1; B2R-ag: 813 µg/kg.day-1) [10], associated or 
not with the specific B2R antagonist (HOE140, Icatibant, B2R-ant)[24] at a dose of 380 
nmol/kg.day-1 (500 µg/kg.day-1) [25]. B2R-ant was also administered alone at the same 
dosage. Control mice received only vehicle (Phosphate Buffered Saline, PBS). Treatments 
were pursued until sacrifice (n=7-30/group).  
Histological analysis Skin biopsies fixed in 10% formalin and embedded in paraffin were 
cut into 7-µm section and stained with Masson’s trichrome according to the manufacturer’s 
instructions (Sigma-Aldrich, France). Photomicrographs were obtained using digital camera 
attached to light microscope (Leica DM 4000B and LAS v3.8 software). Epidermal thickness 
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was measured in wounded skin and healthy surroundings area by using Image Analyzer 
Software (ImageJ, NIH) (3 measurements for each compartment/section, 4 sections/animal, 
n=7-13/group). Structure and organisation of the granulation tissue and/or the scar were 
observed. 
 
Wound closure and histological studies were performed blindly with regard to treatment. 
 
Measurement of kinin receptors and cytokines mRNA level and circulating MCP-1 and 
SAP Real time PCR was performed to assess B1R and B2R mRNA levels. Total RNA was 
isolated from the skin, collected at day 11, using TRIzol (Invitrogen, France) and reverse 
transcribed with superscript II reverse transcriptase as previously described[26]. The cDNAs 
were amplified and quantified using TaqMan Universal Master Mix and Assays-on-Demand 
Gene Expression Probes for gene of B1R and B2R (Applied Biosystems, France) in an ABI 
PRISM-7000 Sequence Detection System (Applied Biosystems, France). Each sample was 
tested in triplicate. Data were normalized to 18S rRNA. Changes in the target gene were 
calculated by the 2-∆∆CT comparative method for each sample[27]. Same protocol was used to 
determine levels of MCP-1, TNF-alpha, TGF-beta and IL-6, four major pro-inflammatory 
cytokines, in wounded skin, using probes from the same supplier. Plasma MCP-1 
concentration was also determined in blood samples at 11 days using a mouse MCP-1 
enzyme-linked immunosorbent assay kit (Invitrogen, France) according to the manufacturer’s 
instructions. Serum Amyloid P (SAP), an inflammatory marker equivalent to C-reactive 
protein in man, was quantified at 11 days using a mouse Elisa test kit (Life Diagnosctic, UK). 
 
Keratinocytes and fibroblasts cell culture 
 
Keratinocytes (human keratinocyte cell line HaCaT; ATCC, Virginia) were cultured in 
Dulbecco's Modified Eagle Medium (DMEM, Glucose concentration 4500 mg/l, Gibco, 
LifeTechnologies, UK) supplemented with 10% Foetal Bovine Serum (FBS, Gibco, 
LifeTechnologies, UK) and antibiotics (50 U/mL Penicillin, 50 U/mL Streptomycin, Gibco, 
LifeTechnologies, UK). Keratinocytes were used between passages 68 and 75.  
 
Fibroblasts (NIH-3T3 mouse fibroblasts; Sigma-Aldrich, Missouri) were cultured in 
DMEM supplemented with 5% New Born Calf Serum (NBCS, Gibco, LifeTechnologies, 
UK), 5% FBS and antibiotics according to manufacturer’s guidelines. Fibroblasts were used 
between passages 162 and 171. 
 
Keratinocytes and fibroblasts were kept at 37°C in a 5% CO2 environment. Culture media 
were changed every two-day. When the cells reached subconfluence, they were harvested 
using 0.05% trypsin–EDTA (Gibco, LifeTechnologies, UK), and fresh culture medium was 
added for obtaining single cell suspensions used for further study. 
 
Cell proliferation assay Cell proliferation was measured using Quick Cell Proliferation 
Assay kit (Abcam, Cambridge, MA) according to the manufacturer's instructions[28]. This 
assay is based on cleavage of the tetrazolium salt WST-1 to formazan by cellular 
mitochondrial dehydrogenases. Briefly, keratinocytes or fibroblasts were seeded on 96-well 
plates (1x104 cells/well) and incubated with two different concentrations of B1R-ag or B2R-
ag (1x10-6 mol.L-1 and 1x10-7 mol.L-1) and/or with B2R-ant (1x10-5 mol.L-1) in DMEM 
supplemented with 2% FBS. Cell proliferation was measured after 24, 48, 72 and 96 hours of 
incubation. Optical density was measured at 440 nm with a reference wavelength of 650 nm 
using a precision microplate reader (iMark Microplate Absorbance Reader, BIORAD). 
 
 
 
 
7 
Results were expressed as percentage of control (DMEM supplemented with 2% FBS). Each 
experiment was performed in duplicate per condition and repeated three times. 
 
Wound closure assay Spreading and migration capabilities of cells were assessed using a 
scratch assay[29]. Keratinocytes or fibroblasts were seeded on 6-well plates (3x105 
cells/well). After reaching confluence, cultures were scratch-wounded with a 0.2 ml sterile 
pipette tip at the centre of each well and cell debris were removed by PBS washing. For 
keratinocytes, plates were pre-coated with collagen I (BD Biosciences, California). B1R-ag or 
B2R-ag (1x10-6 mol.L-1  and 1x10-7 mol.L-1) and/or B2R-ant (1x10-5 mol.L-1) were added in 
DMEM supplemented with 2% FBS. Mitomycin C (Sigma-Aldrich, Missouri) (10µg/mL) was 
also added in medium to inhibit cellular proliferation. After 15 hours, photographs of the 
scratch width were taken every 3 hours until closure and scratch closure was quantified by 
monitoring the front of migration. Results were expressed in percentage of scratch width 
measured at hour 0. Each experiment was realized in duplicate per condition and repeated 
four times. 
 
Western blotting Cells were deprived in FBS during 24 hours and then treated 0, 2, 5, 15 
and 40 minutes with B2R-ag (1x10-6 mol.L-1) and/or B2R-ant (1x10-5 mol.L-1). Proteins were 
extracted from treated-cells using standard protein extraction protocols and were dosed using 
BCA protein assay (Pierce Protein Biology Products, USA). Fifteen-µg proteins were 
separated on a Mini-PROTEAN TGX gel (Biorad, USA) and membranes were blotted with 
phospho- and total p44/42 MAPK (Erk-1/2) (Thr202/Tyr204) rabbit antibody (dilution 
1/1000; Cell signalling technologies, Danvers, USA). They were exposed to ECL plus 
western blotting reagents (Biorad, USA) and reactive bands were detected in ImageQuant 
LAS 4000 (GE Healthcare, France) and quantified using Multi Gauge software 2.0 (FujiFilm, 
Japan). Each blot was then stripped and re-probed with anti-β-actin antibodies for data 
normalization. Results were confirmed by repeating the experiment 3–5 times. 
 
Statistical analysis 
 
Data are presented as mean±SEM. Statistical analysis was performed using one-way or 
two-way ANOVA for comparing effect of diabetes and/or treatments in mice. One-way 
ANOVA was used for comparing effect of treatment on cell migration or proliferation and 
effect of diabetes on receptor mRNA level. ANOVA was followed by ad-hoc multiple 
comparison tests. Statistical significance was accepted at p<0.05. 
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Results 
 
Treatments did not affect metabolic parameters. Body weight and plasma glucose level of 
the different groups of mice at the beginning and end of the experiment are presented in 
Table1. Treatment with B1R-ag, B2R-ag and/or B2R-ant did not affect these parameters 
(Table 1).  
 
B1R and B2R mRNA levels are increased in diabetic skin. Analysis of bradykinin receptor 
levels in healthy skin and wounded area at day 11 demonstrated that B1R mRNA level were 
increased roughly 3 times in STZ-Diab mice compared to NonDiab mice (p<0.01). Similarly, 
B2R mRNA level were also increased 2 times compared to Non-Diab mice (p<0.01) (Fig.1).  
 
B1R agonist treatment had no effect on wound closure. B1R-ag treatment had no effect on 
wound closure in NonDiab mice (Fig.2A) and in STZ-Diab mice (Fig.2B). Moreover, 
histological analysis showed that B1R activation did not alter skin organisation and had no 
effect on epidermal thickness, neither in intact surrounding skin nor in wounded skin (data not 
shown). 
 
B2R activation delays wound closure in mice. In NonDiab mice, B2R-ag treatment 
significantly delayed wound healing from the 1st day of treatment onward (Fig.2A). Co-
treatment with the B2R-ant totally abrogated the wound healing delaying effect of B2R-ag. 
Kinetic profile of wound closure in mice co-treated with B2R-ag and B2R-ant was 
indistinguishable from PBS-treated mice (Fig.2A). In STZ-Diab mice, wound closure was 
significantly delayed when compared with NonDiab mice (Fig.2B). On day 11, wounds were 
healed in NonDiab mice whereas they remained open in STZ-Diab mice (12.7 ± 1.2 %, 
p<0.05). In STZ-Diab mice, B2R-ag treatment resulted in a further significant delay in wound 
healing from the 1st day of treatment onward (Fig.2B). On day 11, wound area was 2.3 times 
larger in B2R-ag-treated STZ-Diab mice compared to PBS-treated STZ-Diab mice (p<0.05).  
 
B2R blockade improves skin wound healing in two models of diabetic mice. B2R-ant alone 
had no significant effect on wound healing in NonDiab mice (Fig.2A) but significantly 
improved skin wound healing in diabetic mice. In STZ-Diab mice, wound area was reduced 
on the 1st day of B2R-ant treatment and was indistinguishable from NonDiab mice during the 
11 days follow-up period (Fig.2B). The beneficial effect of B2R-ant on wound healing was 
also observed in another diabetic model, db/db-Diab mice. In these mice, B2R-ant 
significantly reduced wound area during the 11th days of treatment (Fig.2C). On day 11, 
wound area was 3.2 times smaller in B2R-ant-treated db/db-Diab mice compared to PBS-
treated db/db-Diab mice (p<0.05).  
 
B2R activation induces epidermal thickening and skin layer disorganization in wounded 
skin. B2R activation induced no alteration in intact part of skin in NonDiab and STZ-Diab 
mice (data not shown). But, in the wound of NonDiab and Diab mice, B2R-ag treatment 
induced skin layer disorganisation, with a defect in skin and epidermal maturation, 
hypervascularisation and hypercellularisation of granulation tissue (Fig.3A). In B2R-ag-
treated NonDiab mice, epidermal thickness of wound area was increased compared to PBS-
treated mice (111.1±8.7 µm vs 69.9±5.7 µm; p<0.05). This effect was abrogated by co-
treatment with B2R-ant (56.3±8.2 µm; p<0.05) (Fig.3B). In Diab mice, treatment with B2R-
ag had no further effect on epidermal thickness (Fig.3C).   
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B2R antagonist treatment restores wounded skin histology in diabetic mice. After B2R-ant 
treatment alone, the epidermis of Diab-mice was histologically indistinguishable from 
NonDiab mice (Fig.3A). B2R-ant decreased by 45% the epidermal thickness of diabetic 
wounds (112.4±21.9 µm vs 206.3±21.6 µm; p<0.05) (Fig.3C).  
 
B2R-ant treatment increases mRNA level of MCP-1 and TNF-alpha. IL-6 and TGF-beta 
mRNA levels were not influenced by B2R-ag or B2R-ant treatment (data not shown). MCP-1 
and TNF-alpha mRNA levels were not influenced by B2R-ag treatment but B2R-ant 
treatment significantly increased both mRNAs in the wounded skin compared to PBS-treated 
Diab-mice (Fig.4). However, treatment had no effect on plasma concentration of MCP-1 
(Fig.4). Concentration of SAP was below detection level in all groups (data not shown). 
 
B2R activation unbalances keratinocyte and fibroblast proliferation in vitro. Treatment 
with B1R-ag or B2R-ag significantly increased keratinocyte proliferation, assayed using 
Quick Cell Proliferation Assay kit (+36% to 46% at 48h, p<0.05) (Fig.5A). Moreover, 
fibroblast proliferation was significantly decreased by the B2R-ag (-33% at 48h, p<0.05) but 
was not altered by the B1R-ag (Fig.5B). These B2R-ag effects on cell proliferation were 
abolished by co-treatment with B2R-ant (Fig.5). B2R-ant alone had no effect on cell 
proliferation. 
 
B2R activation stimulates keratinocyte but not fibroblast migration. Figure 6 shows that 
keratinocyte migration, assessed using scratch assay, was significantly stimulated with B2R-
ag during the 30 hours scratch closure process and independently of the dose used (wound 
closure +32% compared to medium alone after 24h, p<0.05). This effect was abolished in 
presence of the B2R-ant (Fig.6B). B2R-ant alone or B1R-ag had no effect on cell migration 
(Fig.6B). B2R-ag treatment had no effect on fibroblast migration (data not shown).  
 
B2R activation induces ERK phosphorylation in keratinocytes. B2R-ag induced 
phosphorylation of ERK-1/2 in keratinocytes. Peak phosphorylation occurred 5 to 40 min 
after stimulation (p<0.05) and thereafter, the phosphorylation level gradually decreased (60-
120 min). This effect was blocked by B2R-ant co-treatment (Fig.7).  
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Discussion  
The main findings of the present study are that kinin B2R activation delays healing in non-
diabetic and diabetic mouse skin wound models. Treatment with a selective B2R antagonist 
accelerates skin wound repair in diabetic mice. The healing effect of B2R antagonist was 
consistent in two different murine models of diabetes, close to either type 1 or type 2 human 
diabetes. The deleterious effects of B2R activity in the wounded skin may involve 
unbalancing of keratinocyte and fibroblast proliferation during the re-epithelialisation and 
scar remodelling phases after injury.  
	  
Previous reports indicated that B1R and B2R are present in healthy human skin and in skin 
of patients with cutaneous wound or proliferative skin diseases[12-14]. We show that both 
receptors are present in murine skin and are upregulated by diabetes mellitus.  
Kinins can exert their biological actions through these two types of G protein-coupled 
membrane receptors. While the B2R is constitutively present in most tissues and mediates the 
main effect of kinins, the B1R is considered as being mainly inducible and its functions are 
less well understood. Interestingly, we recently showed that B1R activation protects the heart 
against ischemia damage[30] and has pro-angiogenic effects in a diabetic mouse model of 
hindlimb ischemia[10]. However in the skin, B1R activation had no effect on wound healing 
in mice, diabetic or non-diabetic. This receptor does not seem to be importantly involved in 
control of skin trophicity in diabetes, despite its strong induction by chronic hyperglycaemia.  
By contrast, B2R activation disorganized the architecture of the wound, increased 
epidermis thickness and significantly delayed wound healing in mice. The deleterious effect 
of B2R activation on wound repair was observed in both non-diabetic and diabetic mice and 
was additive to the effect of diabetes. Co-treatment with a specific B2R antagonist abrogated 
the effects of B2R agonist administration indicating that these effects were truly due to B2R 
activation.  
	  
Wound healing involves tightly regulated humoral and cellular processes. Alteration of 
these timely-controlled processes by chronic hyperglycaemia expands tissue damage and 
delays tissue repair[31]. After a cutaneous injury, the healing process can be divided into four 
successive, overlapping phases: coagulation, inflammation, cell migration and proliferation, 
and remodelling. Kinins, through B2R activation, could likely influence several of these 
phases.  
 The first steps of wound healing are haemostasis and inflammation[31]. Kinins, through 
vascular endothelium activation, have anti-clotting and profibrinolytic effects[32,33], increase 
blood flow and trigger leucocyte migration[34]. In our study, pharmacological manipulation 
of B2R activity influenced wound repair already on the first day of follow-up after surgery.  
This observation suggests that kinins influence the initial phase of wound repair. The absence 
of effect of B2R agonist treatment on inflammatory markers in plasma or on cytokine gene 
expression in scar suggests that inflammation does not play an important role in B2R effect in 
wounded skin. On the other hand, B2R antagonist induced gene expression of MCP-1 and 
TNF-alpha, two cytokines previously shown to be involved in wound repair that may thus 
mediate, at least in part, the beneficial effect of B2R inhibition [35,36]. The mechanism of 
MCP-1 and TNF-alpha induction during B2R inhibition remains however undocumented.  
 
Kinins can also influence late phases of healing. Our histological results show that B2R 
agonist induced skin disorganisation and increased epidermal thickness and hypercellular 
granulation tissue. Moreover, previous studies suggested that bradykinin enhances 
keratinocyte motility[37] and differentiation even if effect on cell proliferation is 
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unclear[13,15]. All these findings suggest that kinins influence proliferative and remodelling 
phases of healing. In this context, we studied in vitro effect of B2R activation on proliferation 
and migration of the two major cell types involved in scar formation: keratinocytes and 
fibroblasts. Our results show that B2R activation inhibited fibroblast proliferation but 
increased keratinocyte proliferation and migration in a cell layer injury model. Despite 
limitation in extrapolation of data from in vitro to in vivo settings due to use of established 
cell lines and different species, these effects of B2R agonist are consistent with the wound 
repair delaying effect observed in mice. Indeed, accumulation of fibroblasts, formation of 
granulation tissue, reconstitution of the dermis and reformation of an intact epidermis via 
keratinocyte migration and proliferation are important features of the wound healing 
process[31]. Skin layer disorganization, involving stratum corneum, epidermis and dermis, 
observed in mice treated with B2R agonist, especially in diabetic mice, may thus reflect 
unbalance between hypo-proliferation of fibroblasts and hyper-proliferation of keratinocytes, 
impairing healing. Stimulation of keratinocyte proliferation and migration in vitro by B2R 
activation is in line with the thickening of epidermis observed in B2R agonist treated mice. 
B2R activation effects on keratinocytes were associated with ERK-1/2 phosphorylation. 
This result is in agreement with previous observations showing that keratinocyte migration, 
proliferation and wound re-epithelialization involve ERK activation[38-40] and confirms the 
importance of this pathway in keratinocyte functionality. 
	  
The deleterious effect of B2R stimulation on wound healing was additive to the effect of 
diabetes. Abnormal keratinocyte and fibroblast migration, proliferation and differentiation, 
and decreased vascularisation contribute to delayed wound healing in diabetic patients[4,41]. 
In these patients, keratinocytes in epidermis of chronic ulcers are highly proliferative[42]. 
B2R agonist treatment probably worsened keratinocyte hyper-proliferation due to diabetes 
and stimulated migration, resulting in abnormal scar remodelling.  
 
Interestingly, whereas B2R antagonist alone had no effect on the wounded skin in non-
diabetic mice, it significantly accelerated wound repair in diabetic mice. Indeed, B2R 
blockade restored the normal proliferation and maturation pattern of the wounded epidermis 
in a murine model of type 1 diabetes (STZ). The beneficial effect on wound healing of B2R 
antagonist was extended to a second diabetic mouse model, closer to type 2 human diabetes 
(db/db mice). These observations indicate that endogenous kinins exert deleterious effects 
opposing wound repair in diabetic skin. The lack of effect of B2R antagonist in non-diabetic 
mice may be explained by low kinins bioavailability and/or reduced B2R synthesis in the skin 
in normoglycaemic condition. By contrast, in diabetes, B2R synthesis is upregulated in the 
skin and kinins production may also be enhanced.  
 
The study highlights the organ specificity and duality of action of B2R. B2R activation 
simultaneously aggravates tissue damage in the wounded skin and reduces ischemic or 
hyperglycaemic tissue damage in heart and kidney[11,26,43]. Kinins are mainly inactivated in 
the circulation by the angiotensin I-converting enzyme (ACE/kininase II). ACE inhibitors 
increase kinin biodisponibility and are largely used clinically in a number of cardiovascular 
and renal indications, including in diabetes. No side effect related to impairment of skin 
wound healing or aggravation of diabetic ulcers has however been reported in clinical trials 
with ACE inhibitors. ACE inhibitors have not been studied experimentally in wound healing 
but angiotensin II type 1 receptor (AT1R) blockers and AT1R gene inactivated mice have 
been shown to display delayed skin wound healing in both non-diabetic and diabetic 
conditions[44]. As AT1R inhibition triggers angiotensin II type 2 receptor (AT2R) 
stimulation and subsequent kinin formation and B2R activation[45,46], kinins might be 
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involved in the deleterious effect of AT1R blockade observed experimentally in the skin, 
although this remains speculative. Like for ACE inhibitors no side effect related to skin 
healing has been observed in clinical trials with AT1R blockers. In our study, the absence of 
effect of B2R antagonist in non-diabetic mice may be explained by low kinins bioavailability 
and/or reduced B2R synthesis in the skin in normoglycaemic condition. By contrast, in 
diabetes B2R synthesis is upregulated in the skin and kinin production may also be enhanced. 
Kinins are produced by tissue kallikrein and/or activated plasma prekallikrein. Tissue 
kallikrein is present in the skin[12,14,15]. However, in tissue kallikrein deficient mice[7,47], 
either rendered diabetic or not, we did not observe any alteration in wound repair, suggesting 
that tissue kallikrein is not importantly involved in kinin production in the wounded skin 
(unpublished results). On the other hand, plasma prekallikrein increases in diabetes[48] and 
this enzyme might be responsible for kinins production in the wounded skin, although this 
remains speculative. 
 
In conclusion, B2R but not B1R activation exerts deleterious effects in the wounded mouse 
skin resulting in delayed healing, especially in diabetic animals. B1R and B2R are 
upregulated by diabetes in skin. Treatment with a B2R antagonist accelerates wound repair in 
two different mouse models of diabetes. Improving skin healing is still a therapeutic issue in 
diabetic patients, especially for treatment of foot ulcers. These results indicate that 
investigation of kinin B2 antagonism in human diabetic wound healing is warranted, and that 
kinin B2R antagonism could become a new treatment for cutaneous injury. It is worth noting 
that icatibant, a first generation pseudopeptide kinin B2R antagonist synthesized decades 
ago[24], has recently been approved for clinical use in an unrelated indication, angioedema 
[49]. 
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Clinical perspectives 
 
- Impairment of skin wound repair is a major complication of diabetes, favouring 
development of foot ulcers and contributing to their poor prognosis. Improving skin healing is 
a therapeutic issue in diabetic patients. 
- Our study revealed that treatment with a kinin B2-receptor antagonist normalizes wound 
repair in two mouse models of diabetes, close to either type 1 or type 2 human diabetes.  
- B2-receptor antagonism, already approved clinically in an unrelated indication, may 
become new treatment for cutaneous injury in diabetic patients. 
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TABLE 1: Weight and blood glucose level of different experimental groups at time of 
wounding (beginning of the experiment) and 11 days after wounding (end of the experiment). 
 
 
 
 
 
n 
Beginning of experiment End of experiment 
Weight  
(g) 
Blood glucose 
(mg/dL) 
Weight  
(g) 
Blood glucose 
(mg/dL) 
NonDiab 30 26.2 ± 0.5 178 ± 6 25.7 ± 0.4 156 ± 12 
STZ-Diab      
PBS-treated 22 23.3 ± 0.2 471 ± 17 ** 22.8 ± 0.3 464 ± 13 ** 
B1R-ag-treated  21 23.5 ± 0.2 500 ± 17 ** 23.9 ± 0.2 452 ± 21 ** 
B2R-ag-treated  20 22.5 ± 0.2 456 ± 26 ** 23.3 ± 0.3 438 ± 32 ** 
B2R-ant-treated  7 23.0 ± 0.3 460 ± 34 ** 24.0 ± 0.5 453 ± 26 ** 
db/db mice      
PBS-treated  10 43.2 ± 0.9 386 ± 25 ** 44.5 ± 1.2 379 ± 27 ** 
B2R-ant-treated  10 43.5 ± 0.4 385 ± 34 ** 45.8 ± 0.8 394 ± 29 ** 
 
** p<0.001: glucose level in all Diab groups vs NonDiab. NS among Diab groups.  
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Figure legends 
 
Fig.1: B1R and B2R mRNA levels are increased in diabetic skin. 
Kinin receptor mRNA level in non-diabetic and diabetic mouse skin (wounded or not), 
measured by RT-qPCR. Data were normalized to 18S rRNA. Data are mean±SEM, 
n=7/group. **:p<0.01 Diab vs NonDiab 
 
Fig.2: B2R but not B1R activation influences wound healing in NonDiab mice and in Diab 
mice. 
Representative photographs of wound area at day 0 and 11 and time course of wound closure 
(A: NonDiab mice; B: STZ-Diab mice; C: db/db-Diab mice). Results are expressed in 
percentage of initial wound area at day 0. Data are mean±SEM, n=7-30/group. *:p<0.05 and 
**:p<0.01 vs PBS-control in each series; $:p<0.05 and $$:p<0.01 Diab vs NonDiab. 
 
Fig.3: B2R but not B1R activation increases epidermal thickness and worsens skin 
disorganization in wounded skin in NonDiab and STZ-Diab mice. 
(A) Representative photographs of Massons’s trichrome-stained sections of wounds at day 11 
(2x; 10x; 25xmagnification) documenting change in the skin organization. Note thickness of 
epidermis and vascularisation and cellularisation of dermis. Bar = 1mm. Blue arrows show 
hypercellularisation, black arrows hypervascularisation, dashed blue arrow epidermal 
thickening and dashed black arrows skin layer disorganisation. (B) Quantification of 
epidermal thickness of the scar in NonDiab mice. (C) Quantification of epidermal thickness 
of the scar in STZ-Diab mice. Data are mean±SEM, n=7/group.  
 
Fig.4: B2R-ant treatment increases mRNA level of MCP-1 and TNF-alpha. 
(A) MCP-1 and TNF-alpha mRNA level in scar of STZ-Diab mice treated with the B2R-ag or 
B2R-ant, measured by RT-qPCR. Data were normalized to 18S rRNA.  (B) MCP-1 protein 
level in plasma of these mice. Data are mean±SEM, n=5-6/group.  
 
Fig.5: B2R activation unbalances keratinocytes/fibroblasts proliferation. 
Cell proliferation after 48h of treatment with B1R-ag, B2R-ag and/or B2R-ant (A: 
keratinocytes; B: fibroblasts) at indicated doses. Data are mean±SEM, n=6 wells/group.  
 
Fig.6: B2R but not B1R activation stimulates keratinocyte migration. 
(A) Representative images of keratinocytes migration (10×magnification) at 0, 15 and 30h 
post scratch. Scratch area is delimited by black box. (B) Scratch closure after 24h of 
treatment. Data are mean±SEM and expressed as percentage of scratch width measured at 0h. 
Each data point represents n=8 wells.  
 
Fig.7: B2R activation induces ERK phosphorylation in keratinocytes. 
Phosphorylation of ERK-1/2 on keratinocyte lysates assessed by Western blotting after 0, 2, 
5, 15 and 40 minutes of tretament with B2R-ag (1x10-6 mol.L-1) and/or B2R-ant (1x10-5 mol.L-
1). Results are representative of 3-5 independent experiments. *:p<0.05 vs t=0min. 
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Summary statements   
 
Kinin B2-receptor activation impairs skin wound healing in mice, in part through 
imbalance of keratinocyte/fibroblast proliferation. Such activation occurs in diabetes and 
contributes to delaying wound healing. B2-receptor blockade restores normal wound healing 
pattern in mouse models of diabetes. 
 







